69f73cc3_anderbilt_Ingram_Cancer_Center__Trial_Type
[Protocol No. & Open Date] VICCURO1382 02/10/2014 [Summary] A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer [Trial Type] 
Treatment Bladder
Urologic / Genitourinary Cancers - Vanderbilt-Ingram Cancer Center
Trial Type